luveltamab tazevibulin (STRO-002) - Sutro Biopharma
Preclinical characterization of STRO-002, a clinical-stage anti-FolRα antibody-drug conjugate. (AACR-NCI-EORTC 2023) - Sep 16, 2023 - Abstract #C115; Pres time: Oct 14, 2023; 12:30 PM - 04:00 PM; Location: LEVEL 2, EXHIBIT HALL D; No abstract available 
Preclinical • Oncology
https://www.aacr.org/wp-content/uploads/2023/09/MTCT2023_postersC_titles.pdf
 
Robert Yuan
 
Sep 16, 2023
 
Prev Next